GlassScriptPhysician profile
Baruch D Kuppermann
NPI 1326128455
$1,048,681.92
in general payments reported to CMS, 2019-2025
26 companies · $426K in 2025
The $426K reported for 2025 was more than what 99% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $43K · 2021: $29K · 2022: $27K · 2023: $80K · 2024: $293K · 2025: $426K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $711K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Honoraria: $21K · Travel and Lodging: $14K · Food and Beverage: $6,770 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $710,794.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,552.99 |
| Honoraria | $21,200.00 |
| Travel and Lodging | $13,966.13 |
| Food and Beverage | $6,770.23 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $652,304.28 | 2023-2025 | Dextenza |
| Allergan, INC. | $214,946.23 | 2019-2022 | |
| Abbvie INC. | $45,669.89 | 2022-2025 | |
| Genentech USA, INC. | $41,709.16 | 2021-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $16,485.95 | 2022-2025 | Syfovre |
| Coherus Oncology, INC. | $16,058.18 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $14,088.61 | 2019-2025 | Eylea Hd, Eylea |
| Amgen INC. | $9,947.00 | 2023-2025 | Pavblu, Lumakras |
| Novartis Pharmaceuticals Corporation | $9,024.19 | 2019-2020 | |
| Hexal Ag | $7,557.00 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $6,984.96 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Eyepoint US, INC. | $6,676.88 | 2023-2024 | |
| F. Hoffmann-La Roche Ag | $4,352.50 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $1,100.00 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $403.21 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $290.72 | 2024 | Senza |
| Regeneron Pharmaceuticals, INC. | $264.61 | 2024-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $173.32 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $162.78 | 2023 | |
| Astellas Pharma US INC | $148.26 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $125.11 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $90.46 | 2022 | |
| Astellas Pharma Global Development | $61.18 | 2024 | Izervay |
| Rxsight INC | $39.93 | 2021 | |
| Glaukos Corporation | $17.51 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baruch Kuppermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.